Monthly Archives: May 2015

ASCO 2015: Abstract Thoughts On Cancer And Competition
May 29, 2015

With the start of the American Society of Clinical Oncology meeting, all eyes in the biopharma investor community are on Chicago. Social media is alive with #ASCO15 tweets and companies big and small are firing out press releases. Signal from

2 Comments

From Crawl to Sprint: The Race to Treat NASH
May 21, 2015

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. Early this week, Intercept Pharmaceuticals announced the much awaited design of their Ph. 3 clinical trial of Obeticholic Acid (OCA)

2 Comments

Reflections On Scientific Advisory Board Construction
May 19, 2015

This blog was written by Kevin Pojasek, co-founder and Acting CEO of Quartet Medicine and Atlas EIR, as part of the “From the Trenches” feature of LifeSciVC. “Most of the smartest people work somewhere else.” The famous Bill Joy quote, often

3 Comments

BioPharma M&A: Capital Efficiency Drives Returns
May 15, 2015

Amidst lofty public markets and robust fund flows, it’s easy to forget the importance of equity capital efficiency in building new biotech companies. But like gravity, it’s a fundamental principle and rests at the heart of generating quality returns in

4 Comments

To Tweet Or Not To Tweet, That Is The Question
May 13, 2015

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. Have you ever scrolled through your Twitter feed and found something distasteful posted about your company? You may be the

Leave a comment

Confronting Real(i)ty In Cambridge
May 6, 2015

This blog was written by Chuck Wilson, CEO of Unum Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. This is an ongoing saga about finding a new home for my company, Unum Therapeutics. Google tells me that there

7 Comments